Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.
References